Nanoparticle Formulation of Indocyanine Green Improves Image-Guided Surgery in a Murine Model of Breast Cancer

Wojtynek, Nicholas E.; Olson, Madeline T.; Bielecki, Timothy A.; An, Wei; Bhat, Aaqib M.; Band, Hamid; Lauer, Scott R.; Silva-Lopez, Edibaldo; Mohs, Aaron M.

doi:10.1007/s11307-019-01462-y

Cited by 14 publications

(11 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To overcome these limitations, new strategies based on novel ICG-conjugated nanoparticles have been developed in order to increase the ICG concentration in the tumor. For instance, ICG-loaded self-assembled hyaluronic acid nanoparticles were able to enhance intraoperative contrast and increase the number of complete breast tumor resections [ 22 , 23 ]. Additionally, liposomal formulations of ICG were able to maximize its photothermal effect, and allowed for photothermal treatment monitored by NIR fluorescence-based imaging [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

The use of a uPAR-targeted probe for photothermal cancer therapy prolongs survival in a xenograft mouse model of glioblastoma

et al. 2021

View full text Add to dashboard Cite

The development of tumor-targeted probes that can efficiently reach cancerous tissue is an important focus of preclinical research. Photothermal cancer therapy (PTT) relies on light-absorbing molecules, which are directed towards tumor tissue and irradiated with an external source of light. This light is transformed into heat, causing localized hyperthermia and tumor death. The fluorescent probe indocyanine green (ICG) is already used as an imaging agent both preclinically and in clinical settings, but its use for PTT is yet to be fully exploited due to its short retention time and non-specific tumor targeting. Therefore, increasing ICG tumor uptake is necessary to improve treatment outcome. The urokinase-type plasminogen activator receptor, uPAR, is overexpressed in multiple tumor types. ICG-Glu-Glu-AE105, consisting of the uPARtargeting peptide AE105 conjugated to ICG, has shown great potential for fluorescenceguided surgery. In this study, ICG-Glu-Glu-AE105 was evaluated as photothermal agent in a subcutaneous mouse model of human glioblastoma. We observed that the photothermal abilities of ICG-Glu-Glu-AE105 triggered high temperatures in the tumor during PTT, leading to tumor death and prolonged survival. This confirms the potential of ICG-Glu-Glu-AE105 as photothermal agent and indicates that it could be used as an add-on to the application of the probe for fluorescence-guided surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

The use of a uPAR-targeted probe for photothermal cancer therapy prolongs survival in a xenograft mouse model of glioblastoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…One area of active research in image-guided approaches NPs carrying ICG can also be designed to target tumor cells by conjugation with folic acid, hyaluronic acid, or antibodies against tumor-specific surface receptors (51). Wojtynek et al (54) developed ICG-loaded hyaluronic acid NPs (approximately 70 nm in size) that could provide stronger contrast enhancement of tumors in the 800-nm channels than that provided by ICG, which gives weak fluorescence at the 800-nm channel. The group demonstrated the efficacy of these NPs in complete breast tumor resection and postsurgery survival in tumor-bearing mice.…”

Section: Image-guided Cancer Interventionsmentioning

confidence: 99%

Nanotechnology for Cancer Imaging: Advances, Challenges, and Clinical Opportunities

Liu

Grodzinski

2021

Radiology: Imaging Cancer

View full text Add to dashboard Cite

Nanoparticle (NP) imaging applications have the potential to improve cancer diagnostics, therapeutics, and treatment management. In biomedical research and clinical practice, NPs can serve as labels or labeled carriers for monitoring drug delivery or serve as imaging agents for enhanced imaging contrast, as well as providing improved signal sensitivity and specificity for in vivo imaging of molecular and cellular processes. These qualities offer exciting opportunities for NP-based imaging agents to address current limitations in oncologic imaging. Despite substantial advancements in NP design and development, very few NP-based imaging agents have translated into clinics within the past 5 years. This review highlights some promising NP-enabled imaging techniques and their potential to address current clinical cancer imaging limitations. Although most examples provided herein are from the preclinical space, discussed imaging solutions could offer unique in vivo tools to solve biologic questions, improve cancer treatment effectiveness, and inspire clinical translation innovation to improve patient care.

show abstract

“…Fluorescence intensity of NanoICG was compared with ICG and showed to be 2.2-fold higher, as seen in Figure 4b. Pancreatic tumors and metastasis were more clearly delineated with NanoICG signals, with negligible toxicity attributed to the nanoparticles, highlighting the potential of NanoICG as a surgical imaging contrast agent in comparison to fluorophores alone (Qi et al, 2018;Wojtynek et al, 2019). Another study by Zeng et al formulated a mesoporous silica nanoparticle conjugated with an RGD peptide that was loaded with ICG.…”

Section: Intraoperative Surgical Image Guidance: Preclinical Applicationsmentioning

confidence: 99%

A path toward the clinical translation of nano‐based imaging contrast agents

Miyasato

Mohamed

Zavaleta

2021

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Recently, nanoparticles have evolved ubiquitously in therapeutic applications to treat a range of diseases. Despite their regular use as therapeutic agents in the clinic, we have yet to see much progress in their clinical translation as diagnostic imaging agents. Several clinical and preclinical studies support their use as imaging contrast agents, but their use in the clinical setting has been limited to off‐label imaging procedures (i.e., Feraheme). Since diagnostic imaging has been historically used as an exploratory tool to rule out disease or to screen patients for various cancers, nanoparticle toxicity remains a concern, especially when introducing exogenous contrast agents into a potentially healthy patient population, perhaps rationalizing why several nano‐based therapeutic agents have been clinically translated before nano‐based imaging agents. Another potential hindrance toward their clinical translation could be their market potential, as most therapeutic drugs have higher earning potential than small‐molecule imaging contrast agents. With these considerations in mind, perhaps a clinical path forward for nano‐based imaging contrast agents is to help guide/manage therapy. Several studies have demonstrated the ability of nanoparticles to produce more accurate imaging preoperatively, intraoperatively, and postoperatively. These applications illustrate a more reliable method of cancer detection and treatment that can prevent incomplete tumor resection and incorrect assessment of tumor progression following treatment. The aim of this review is to highlight the research that supports the use of nanoparticles in biomedical imaging applications and offer a new perspective to illustrate how nano‐based imaging agents have the potential to better inform therapeutic decisions. This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging

show abstract

Nanoparticle Formulation of Indocyanine Green Improves Image-Guided Surgery in a Murine Model of Breast Cancer

Cited by 14 publications

References 63 publications

The use of a uPAR-targeted probe for photothermal cancer therapy prolongs survival in a xenograft mouse model of glioblastoma

The use of a uPAR-targeted probe for photothermal cancer therapy prolongs survival in a xenograft mouse model of glioblastoma

Nanotechnology for Cancer Imaging: Advances, Challenges, and Clinical Opportunities

A path toward the clinical translation of nano‐based imaging contrast agents

Contact Info

Product

Resources

About